{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:48:14Z","timestamp":1791402494451,"version":"4.3.3"},"reference-count":90,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heart failure with reduced ejection fraction (HFrEF) is a complex clinical syndrome with significant morbidity and mortality and seems to be responsible for approximately 50% of heart failure cases and hospitalizations worldwide. First-line treatments of patients with HFrEF, according to the ESC and AHA guidelines, include \u03b2-blockers, angiotensin receptor\/neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists. This quadruple therapy should be initiated during hospital stay and uptitrated to maximum doses within 6 weeks after discharge according to large multicenter controlled trials. Quadruple therapy improves survival by approximately 8 years for a 55-year-old heart failure patient. Additional therapeutic strategies targeting other signaling pathways such as ivabradine, digoxin, and isosorbide dinitrate and hydralazine combination for African Americans, as well as adjunctive symptomatic therapies, seem to be necessary in the management of HFrEF. Although second-line medications have not achieved improvements in mortality, they seem to decrease heart failure hospitalizations. There are novel medical therapies including vericiguat, omecamtiv mecarbil, genetic and cellular therapies, and mitochondria-targeted therapies. Moreover, mitraclip for significant mitral valve regurgitation, ablation in specific atrial fibrillation cases, omecamtiv mecarbil are options under evaluation in clinical trials. Finally, the HeartMate 3 magnetically levitated centrifugal left ventricular assist device (LVAD) has extended 5-year survival for stage D HF patients who are candidates for an LVAD.<\/jats:p>","DOI":"10.3390\/ijms25063113","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:33:06Z","timestamp":1709811186000},"page":"3113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium"],"prefix":"10.3390","volume":"25","author":[{"given":"Christos","family":"Kourek","sequence":"first","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9670","authenticated-orcid":false,"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamantia","family":"Papamichail","sequence":"additional","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-3946","authenticated-orcid":false,"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Tsougos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-3447","authenticated-orcid":false,"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Attikon University Hospital, Medical School of Athens, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Paraskevaidis","sequence":"additional","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","first-page":"13","article-title":"Heart Failure Due to Reduced Ejection Fraction: Medical Management","volume":"95","author":"Chavey","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4070\/kcj.2021.0401","article-title":"Medical Management of Patients with Heart Failure and Reduced Ejection Fraction","volume":"52","author":"Greenberg","year":"2022","journal-title":"Korean Circ. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.17305\/bjbms.2010.2649","article-title":"Predictors of left ventricular remodelling in kidney transplant recipents in the first posttransplant year","volume":"10","author":"Uncanin","year":"2010","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2004.11.061","article-title":"Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease","volume":"45","author":"Wali","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/CVM-2-1-020","article-title":"The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial","volume":"2","author":"Eichhorn","year":"2001","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet, 353, 9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value","volume":"81","author":"Xie","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med., 316, 1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"ref_18","first-page":"7","article-title":"Influence of the angiotensin system on endothelial and smooth muscle cell migration","volume":"137","author":"Bell","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/j.1875-9114.1998.tb03155.x","article-title":"Effects of ACE inhibitor therapy on quality of life in patients with heart failure","volume":"18","author":"Wolfel","year":"1998","journal-title":"Pharmacotherapy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/01.CIR.98.17.1742","article-title":"Improved exercise tolerance after losartan and enalapril in heart failure: Correlation with changes in skeletal muscle myosin heavy chain composition","volume":"98","author":"Vescovo","year":"1998","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators, Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., and Cohn, J.N. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med., 327, 685\u2013691.","DOI":"10.1056\/NEJM199209033271003"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"652421","article-title":"Angiotensin receptor antagonists to prevent sudden death in heart failure: Does the dose matter?","volume":"014","author":"Francia","year":"2014","journal-title":"ISRN Cardiol."},{"key":"ref_24","first-page":"425","article-title":"Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction","volume":"3","author":"Bissessor","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000220400.08128.fa","article-title":"Angiotensin receptor blockade with candesartan in heart failure: Findings from the Candesartan in Heart failure\u2014Assessment of reduction in mortality and morbidity (CHARM) programme","volume":"24","author":"Ostergren","year":"2006","journal-title":"J. Hypertens. Suppl."},{"key":"ref_26","first-page":"6","article-title":"Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives","volume":"3","author":"Vizzardi","year":"2014","journal-title":"Int. J. Cardiol. Heart Vessel."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: Current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjmed.2019.05.012","article-title":"Digoxin Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction","volume":"132","author":"Qamer","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1161\/01.CIR.0000132477.32438.03","article-title":"Digitalis therapy for patients in clinical heart failure","volume":"109","author":"Rahimtoola","year":"2004","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Digitalis Investigation Group (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med., 336, 525\u2013533.","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/eurheartj\/ehv755","article-title":"Agents with vasodilator properties in acute heart failure","volume":"38","author":"Singh","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003495-199400474-00008","article-title":"Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III","volume":"47","author":"Cohn","year":"1994","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","article-title":"Ivabradine: Role in the Chronic Heart Failure Armamentarium","volume":"133","author":"Psotka","year":"2016","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_43","first-page":"464","article-title":"Heart Failure: A Class Review of Pharmacotherapy","volume":"42","author":"Shah","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/ehf2.13564","article-title":"Re-do MitraClip in patients with functional mitral valve regurgitation and advanced heart failure","volume":"8","author":"Kreusser","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_45","first-page":"492","article-title":"Catheter Ablation for Atrial Fibrillation with Heart Failure","volume":"379","author":"Marrouche","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-Year Outcomes in Patients with Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/164_2017_13","article-title":"Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction","volume":"243","author":"Psotka","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41467-017-00176-5","article-title":"Mechanis-tic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil","volume":"8","author":"Hartman","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","article-title":"Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure","volume":"3","author":"Shen","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): A phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Patel, P.H., Nguyen, M., Rodriguez, R., Surani, S., and Udeani, G. (2021). Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management. Cureus, 13.","DOI":"10.7759\/cureus.12419"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchf.2013.09.008","article-title":"Design of a phase 2b trial of intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure: The CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)","volume":"2","author":"Greenberg","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","article-title":"Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients with Heart Failure","volume":"81","author":"Perin","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11897-022-00539-0","article-title":"Mitochondria as Therapeutic Targets in Heart Failure","volume":"19","author":"Schwemmlein","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/cdd.2014.200","article-title":"miR-361-regulated prohibitin inhibits mitochondrial fission and apoptosis and protects heart from ischemia injury","volume":"22","author":"Wang","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm.2282","article-title":"miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ncomms1770","article-title":"miR-484 regulates mitochondrial network through targeting Fis1","volume":"3","author":"Wang","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zeng, C., Duan, F., Hu, J., Luo, B., Huang, B., Lou, X., Sun, X., Li, H., Zhang, X., and Yin, S. (2020). NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox. Biol., 34.","DOI":"10.1016\/j.redox.2020.101523"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13845","DOI":"10.1038\/s41598-021-93234-4","article-title":"Targeting mitochondrial reactive oxygen species-mediated oxidative stress attenuates nicotine-induced cardiac remodeling and dysfunction","volume":"11","author":"Ramalingam","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_66","first-page":"CD008684","article-title":"Coenzyme Q10 for heart failure","volume":"2","author":"Assaf","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCRESAHA.115.303062","article-title":"Inhibiting mitochondrial Na+\/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure","volume":"115","author":"Liu","year":"2014","journal-title":"Circ. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jchf.2014.09.009","article-title":"Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy","volume":"3","author":"Beadle","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/13543776.2016.1211111","article-title":"Pleiotropic mechanisms of action of perhexiline in heart failure","volume":"26","author":"George","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Martin, A.S., Abraham, D.M., Hershberger, K.A., Bhatt, D.P., Mao, L., Cui, H., Liu, J., Liu, X., Muehlbauer, M.J., and Grimsrud, P.A. (2017). Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich\u2019s ataxia cardiomyopathy model. JCI Insight, 2.","DOI":"10.1172\/jci.insight.93885"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.116.022495","article-title":"Normalization of NAD+ Redox Balance as a Therapy for Heart Failure","volume":"134","author":"Lee","year":"2016","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter Mitral-Valve Repair in Patients with Heart Failure","volume":"379","author":"Stone","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa2300213","article-title":"Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation","volume":"388","author":"Stone","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tanaka, Y., Shah, N.S., Passman, R., Greenland, P., Lloyd-Jones, D.M., and Khan, S.S. (2021). Trends in Cardiovascular Mortality Related to Atrial Fibrillation in the United States, 2011 to 2018. J. Am. Heart Assoc., 10.","DOI":"10.1161\/JAHA.120.020163"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.122.059885","article-title":"Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure","volume":"145","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter Ablation for Atrial Fibrillation with Heart Failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14779072.2023.2172402","article-title":"Atrial fibrillation ablation as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF): Evaluating the impact on patient survival","volume":"21","author":"Younes","year":"2023","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gopinathannair, R., Chen, L.Y., Chung, M.K., Cornwell, W.K., Furie, K.L., Lakkireddy, D.R., Marrouche, N.F., Natale, A., Olshansky, B., and Joglar, J.A. (2021). Managing Atrial Fibrillation in Patients with Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ. Arrhythm. Electrophysiol., 14.","DOI":"10.1161\/HAE.0000000000000078"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S1790","DOI":"10.21037\/jtd.2017.10.124","article-title":"The momentum of HeartMate 3: A novel active magnetically levitated centrifugal left ventricular assist device (LVAD)","volume":"10","author":"Chatterjee","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jama.2022.16348","article-title":"Left Ventricular Assist Devices in Advanced Heart Failure","volume":"328","author":"Drazner","year":"2022","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jjcc.2009.05.002","article-title":"Left ventricular diastolic dysfunction in the early stage of chronic kidney disease","volume":"54","author":"Otsuka","year":"2009","journal-title":"J. Cardiol."},{"key":"ref_84","first-page":"100389","article-title":"Aortic stiffness is independently associated with interstitial myocardial fibrosis by native T1 and accelerated in the presence of chronic kidney disease","volume":"24","author":"Chen","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1681\/ASN.2006050462","article-title":"Myocardial ultrasound tissue characterization in patients with chronic renal failure","volume":"18","author":"Salvetti","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2020.03.002","article-title":"Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions\u2014Comparison of uremic, hypertensive and hypertrophic cardiomyopathy","volume":"306","author":"Arcari","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1681\/ASN.V5122024","article-title":"The prognostic im-portance of left ventricular geometry in uremic cardiomyopathy","volume":"5","author":"Foley","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1111\/chf.12030","article-title":"Uremic cardiomyo-pathy: An underdiagnosed disease","volume":"19","author":"Alhaj","year":"2013","journal-title":"Congest. Heart Fail."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejim.2020.04.051","article-title":"Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy","volume":"78","author":"Arcari","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.healun.2023.02.551","article-title":"(536) Outcomes After Renal Transplantation in Patients with Reduced Left Ventricular Ejection Fraction","volume":"42","author":"Kelkar","year":"2023","journal-title":"J. Heart Lung Transplant."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:39Z","timestamp":1760105439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":90,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063113"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063113","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}